These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 7755379)
1. [Recent advances in ovarian cancer chemotherapy from the survival standpoint]. Hatae M; Onishi Y; Maeda Y; Maeda T; Hirano T; Kamitomo M Gan To Kagaku Ryoho; 1995 May; 22(6):718-25. PubMed ID: 7755379 [TBL] [Abstract][Full Text] [Related]
2. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Thigpen T; Vance R; Puneky L; Khansur T Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816 [TBL] [Abstract][Full Text] [Related]
3. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of advanced ovarian cancer. Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262 [TBL] [Abstract][Full Text] [Related]
5. [Consensus and new development in epithelial ovarian cancer chemotherapy in 1995]. Hatae M; Onishi Y; Maeda Y; Nakamura T; Maeda T; Wada T Gan To Kagaku Ryoho; 1995 Aug; 22(9):1182-9. PubMed ID: 7661570 [TBL] [Abstract][Full Text] [Related]
7. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222 [TBL] [Abstract][Full Text] [Related]
8. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer. Markman M Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295 [TBL] [Abstract][Full Text] [Related]
9. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie. du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296 [TBL] [Abstract][Full Text] [Related]
10. Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer. Neijt JP; du Bois A Semin Oncol; 1999 Feb; 26(1 Suppl 2):78-83. PubMed ID: 10190786 [TBL] [Abstract][Full Text] [Related]
11. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Ozols RF Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787 [TBL] [Abstract][Full Text] [Related]
12. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Ozols RF Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119 [TBL] [Abstract][Full Text] [Related]
13. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer]. Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312 [TBL] [Abstract][Full Text] [Related]
15. Options for primary chemotherapy in advanced ovarian cancer: the European perspective. Colombo N; Maggioni A; Vignali M; Parma G; Mangioni C Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S108-13. PubMed ID: 7835793 [TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409 [TBL] [Abstract][Full Text] [Related]
17. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date. Harper P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217 [TBL] [Abstract][Full Text] [Related]
18. The results of a quantitative overview of chemotherapy in advanced ovarian cancer: what can we learn? Stewart LA; Parmar MK Bull Cancer; 1993 Feb; 80(2):146-51. PubMed ID: 8173166 [TBL] [Abstract][Full Text] [Related]
19. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome. Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801 [TBL] [Abstract][Full Text] [Related]
20. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]